乳腺癌患者赫赛汀相关心脏毒性机制及处理  

Trastuzumab associated cardiac adverse effects in breast cancer

作　　者：盛李明[1] 杜向慧[1] 

机构地区：[1]浙江省肿瘤医院放疗科

出　　处：《中国临床药理学与治疗学》2011年第9期1077-1080,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：浙江省教育厅2010年度科研计划项目(Y201019160)

摘　　要：近几年来赫赛汀作为针对人表皮生长因子受体2(human epidermal growth factor receptor-2,HER2)的靶向药物被广泛应用于早期、晚期乳腺癌患者,赫赛汀相关心脏毒性虽然发生率低,但对患者生命具有一定的潜在危险。无症状左室射血分数(LVEF)下降是最常见的心脏毒性事件,通常情况下是可控制和可逆的。赫赛汀相关心脏毒性发生与患者年龄、既往高血压病史和蒽环类为基础的化疗有关。赫赛汀治疗期间需要进行严密的心脏功能监测。Trastuzumab has been used widely for the treatment of women with human epidermal growth factor receptor-2（HER2） overexpressing breast cancer in the early and advanced disease.However,cardiac toxicity has emerged as a rare but potentially serious risk that limits its therapeutic potential in a subset of women.Asymptomatic decreasing left ventricular ejection fraction（LVEF） was a common complication and generally reversible and manageable.The increasing risk of trastuzumab-induced cardiac toxicity may be influenced by factors such as age,hypertension and the use of anthracyclines-based chemotherapy.Rigorous cardiac monitoring should be performed for all patients receiving trastuzumab currently in clinic.

关 键 词：乳腺癌 赫赛汀 心脏毒性 靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]